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Objectives: To determine the factors inﬂuencing the abortion interval (AI) for medical termination of
second-trimester pregnancy using misoprostol.
Materials and Methods: All patients who were admitted for second-trimester pregnancy termination
between January 2008 and August 2013 were reviewed. Those who received either 200 mg or 400 mg of
priming vaginal misoprostol, followed by 200 mg of misoprostol orally at 6-hour intervals were enrolled.
Results: In a total of 101 patients, delivery occurred within 24 hours of commencement in 62 patients
(61%) and within 48 hours in 84 patients (83%), and the median AI was 16.5 hours. One patient (1%) failed
to deliver. The remaining 100 fetuses were delivered successfully, and the median AI was 16.3 hours.
Higher parity [hazard ratio (HR) ¼ 1.28, p ¼ 0.04], the presence of intrauterine fetal demise (HR ¼ 2.66,
p ¼ 0.003), and the presence of premature preterm rupture of membranes (HR ¼ 4.51, p ¼ 0.003) were
associated with shorter AI. Additionally, all women with premature preterm rupture of membranes
delivered successfully within 12 hours; higher parity (odds ratio ¼ 2.12, p ¼ 0.01) and lower fetal birth
body weight (odds ratio ¼ 0.992, p ¼ 0.01) were associated with successful delivery within 12 hours.
There was no signiﬁcant difference in AI in the groups that received different doses of priming vaginal
misoprostol (200 mg vs. 400 mg).
Conclusion: Higher parity, intrauterine fetal demise, and preterm premature rupture of membranes were
associated with shorter AI. The regimen of 200 mg oral misoprostol at 6-hour intervals following a 200 mg
or 400 mg priming vaginal dose is feasible and efﬁcacious for second trimester pregnancy termination.
Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
The termination of a second trimester pregnancy can be
accomplished either medically or surgically. During the last 2 de-
cades, medical methods for induced abortion have become pref-
erable to surgical techniques because of lower maternal mortality
and morbidity rates [1].
Of the various abortifacients available, misoprostol has emerged
as the agent of choice for the induction of labor due to its low cost,
long shelf life at room temperature, ease of administration, andand Gynecology, Far Eastern
Banqiao District, New Taipei
).
bstetrics & Gynecology. Publishedworldwide availability. Although the United States Food and Drug
Administration has not approved the use of misoprostol for medical
abortion, pregnancy was removed from the label as an absolute
contraindication in 2002 [2]. Since then, it has been widely used
off-label for a variety of indications in the practice of obstetrics and
gynecology including medical abortion, the induction of labor,
cervical ripening prior to surgical procedures and the treatment of
postpartum hemorrhage.
Misoprostol is a synthetic prostaglandin E1 analog that is
effective not only in preventing gastric ulcers, but also in inducing
cervical effacement and uterine contractions. The effectiveness of
misoprostol alone for second trimester pregnancy is 80e90% [3].
The potency of misoprostol's effect varies with maternal and fetal
factors, as well as the route of administration, dosing interval, dose,
and cumulative dose. The ideal dosing regimen for second
trimester pregnancy termination remains to be determined.by Elsevier Taiwan LLC. All rights reserved.
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inﬂuencing factors is important for counseling women who need
termination of a second trimester pregnancy; however, few studies
mention such ﬁndings [4,5], and the inclusion criteria in these
studies merely includes cases with fetal anomalies or selected
medical indications. Thus, the aim of this retrospective studywas to
estimate the AI in all enrolled women who needed medical
termination by a combination of vaginal and oral misoprostol and
to identify the factors that affect the AI.
Materials and methods
The medical proﬁles of all patients who were admitted for
medical termination of a second-trimester pregnancy between
January 2008 and August 2013 were reviewed. Previous cesarean
delivery was not considered a contraindication for medical termi-
nation with misoprostol. The Research Ethics Committee of the Far
Eastern Memorial Hospital approved this study.
Those women who received a priming dose of 200 mg or 400 mg
misoprostol administered vaginally on admission, followed by
200 mg of misoprostol orally at 6-hour intervals, were enrolled. The
patient characteristics and AI were recorded. The AI was calculated
from the time of administration of vaginal misoprostol to the time
of delivery of the fetus with labor pains or by surgical evacuation.
STATA software (Version 11.0; Stata Corporation, College Station,
TX, USA) was used for the statistical analyses. The survival curve of
the AI was estimated using the KaplaneMeier method [6]. Cox
proportional-hazards modeling was performed to evaluate the
factors affecting the AI. A value of p < 0.05 was considered
signiﬁcant.
Results
This retrospective study included 101 patients with a median
maternal age of 30 years (Table 1). Thirty-ﬁve patients (35%) had at
least one prior vaginal delivery. Thirty-three patients (33%)
required < 12 hours to terminate the pregnancy, 62 patients (61%)
required < 24 hours to terminate the pregnancy, and 84 patients
(83%) required < 48 hours to terminate the pregnancy (Figure 1A).
The median AI of all 101 patients was 16.5 hours [25e75% inter-
quartile range (IQR)¼ 9.3e32.7 hours]. One patient failed to deliverTable 1
Baseline characteristics of patients receiving misoprostol for the termination of
second trimester pregnancy (n ¼ 101).
Variables Valuesa
Maternal age (y) 30 (20e34)
Body mass index (kg/m2) 21.7 (20.2e24.4)
Nulliparous 61 (60)
History of prior vaginal delivery 35 (35)
200 mg priming dose of vaginal misoprostol 53 (52)
Gestational age (wk) 15 (13e17)
Indication for termination
IUFD 13 (13)
PPROM 5 (5)
Fetal anomaly 29 (29)
Other reasonsb 54 (53)
Abortion interval (h)c 16.3 (9.1e32.5)
Delivery within 24 h 62 (61)
Male fetus 49 (49)
BBW (g) 80 (30e160)
BBW ¼ birth body weight; IUFD ¼ intrauterine fetal demise; PPROM ¼ preterm
premature rupture of membranes.
a Median (25e75% interquartile range) or number (%).
b Other reasons: unintended pregnancy.
c The pregnancy not successfully terminated by misoprostol was excluded (i.e.,
n ¼ 100).at 63 hours after misoprostol administration, and the abortion was
completed via cervical dilatation and evacuation. The remaining
100 fetuses were delivered successfully, and themedian AI was 16.3
hours (IQR ¼ 9.1e32.5 hours); however, three patients were later
subjected to placenta evacuation under intravenous anesthesia due
to a retained placenta. There was no difference in AI between the
different doses of priming vaginal misoprostol (200 mg vs. 400 mg;
Figure 1B, log-rank test, p ¼ 0.17).
By the Cox proportional-hazards model, higher parity, the
presence of intrauterine fetal demise and the presence of prema-
ture preterm rupture of membranes were the signiﬁcant factors
associated with shorter AI (Table 2).
Six women had prior cesarean delivery. The method of induc-
tion in women with prior cesarean delivery was no different to
those without. Three of these patients received a 200-mg vaginal
priming dose, while the remaining three patients received a dose of
400 mg. All delivered successfully without any adverse events. The
median AI of womenwith prior cesarean delivery was shorter than
those without (median ¼ 7.9 hours, IQR ¼ 6.1e19.5 hours vs.
median ¼ 17.7 hours, IQR ¼ 9.5e40.6 hours, p ¼ 0.025, log-rank
test). However, when we included prior cesarean delivery in theFigure 1. KaplaneMeier probability curve of time required until fetal expulsion for (A)
all patients undergoing medical termination, and (B) different priming doses of vaginal
misoprostol (200 mg vs. 400 mg).
Table 2
Cox proportional-hazards modeling for factors inﬂuencing the abortion interval of second trimester termination using misoprostol (n ¼ 101).
Variables Univariate analysis Multivariate analysisa
Hazard ratio 95% CI p Hazard ratio 95% CI p
Maternal age (y) 1.03 1.00e1.06 0.03 d d d
Body mass index (kg/m2) 1.03 0.99e1.08 0.15 d d d
Parity 1.27 1.01e1.60 0.04 1.28 1.01e1.62 0.04
Gestational age (wk) 1.04 0.96e1.13 0.33 d d d
The presence of IUFD 3.10 1.66e5.77 < 0.001 2.66 1.39e5.07 0.003
The presence of PPROM 6.73 2.59e17.47 < 0.001 4.51 1.69e12.02 0.003
The presence of fetal anomaly 0.90 0.58e1.41 0.66 d d d
Male fetus 1.05 0.61e1.81 0.87 d d d
Birth body weight (g) 1.00 0.998e1.001 0.74 d d d
Vaginal dose (200 mg ¼ 0, 400 mg ¼ 1) 1.32 0.89e1.96 0.17 d d d
CI ¼ conﬁdence interval; IUFD ¼ intrauterine fetal demise; PPROM ¼ preterm premature rupture of membranes.
a By the backward stepwise method until all the remaining values are p < 0.05.
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delivery disappeared.
If we deﬁned a success as the delivery of the fetus within 12
hours, the presence of premature preterm rupture of membranes
perfectly predicted a success, and higher parity and lower fetal
birth weight were two additional independent factors predicting
success (Table 3).
There were no major maternal morbidities or mortalities during
the course of termination.
Discussion
There were three main factors that signiﬁcantly reduced the AI
in our study: parity; the presence of intrauterine fetal demise; and
preterm premature rupture of membranes. Multiparous women
demonstrated a better response to the regimen with a shorter AI,
which was consistent with the results of a prior study by Dickinson
and Doherty [4] using 400 mg vaginal misoprostol alone at 4-hour
intervals [4]. The median AI was reduced by 37% in multiparous
women compared with the nulliparous women in our study (12
hours vs. 19 hours), a phenomenon that can be explained by better
cervical compliance in the multiparous women. Additionally, we
found that our median AI (16.5 hours) was similar to that of Dick-
inson and Doherty (16.1 hours) [4].
In our study, the presence of intrauterine fetal demise was a
signiﬁcant factor affecting the AI (Table 2). In their prospective
comparison study of second-trimester pregnancy termination us-
ing 200 mg vaginal misoprostol administered every 12 hours, Sri-
somboon and Pongpisuttinun [5] also demonstrated signiﬁcantly
high efﬁcacy formisoprostol in cases of fetal demise comparedwith
live-fetus pregnancy. This may be the result of increasedTable 3
Univariate and multivariate logistic regression analyses for predicting failing inductionwi
Variables Univariate analysis
Odds ratio 95% CI
Maternal age (y) 1.05 0.99e1.10
Body mass index (kg/m2) 1.05 0.96e1.15
Parity 1.68 1.03e2.75
Gestational age (wk) 0.96 0.81e1.14
The presence of IUFD 4.82 1.37e17.0
The presence of PPROM NA NA
The presence of fetal anomaly 0.45 0.17e1.18
Male fetus 3.45 0.88e13.5
Birth body weight (g) 0.995 0.990e1.000
Vaginal dose (200 mg ¼ 0, 400 mg ¼ 1) 1.53 0.68e3.44
NA ¼ not assessable because the presence of PPROM (n ¼ 5) perfectly predicts successfu
CI ¼ conﬁdence interval; IUFD ¼ intrauterine fetal demise; PPROM ¼ preterm prematur
a By the backward stepwise method until all the remaining values are p < 0.05.endogenous production of prostaglandins following the removal of
an inhibitory effect of prostaglandin E2 in the amniotic ﬂuid that
exists with a live fetus [7].
We found that the presence of preterm premature rupture of
membranes was another signiﬁcant independent factor inﬂuencing
the AI and that it perfectly predicted successful delivery within 12
hours (Tables 2 and 3). It has been postulated that the production
and release of prostaglandins and the increase of oxytocinwhen the
fetal membranes are ruptured result in shorter labor [8]. This may
explain the role of preterm premature rupture of membranes in our
study.
The AI of women with prior cesarean delivery was shorter than
those without by the log-rank test; nonetheless, we did not ﬁnd
that the presence of prior cesarean delivery was an independent
factor with the Cox proportional-hazards model, thus the signiﬁ-
cant log-rank test ﬁnding may be merely due to the signiﬁcant
correlation between prior cesarean delivery and parity (Spearman's
rho ¼ 0.29, p ¼ 0.003).
All of six of our patients with prior cesarean delivery had un-
eventful deliveries, and the presence of a prior uterine scar had no
impact on the AI. Herabutya et al [9] also reported that the abortion
interval did not differ between the prior cesarean delivery group
and the control group. Despite the fact that uterine rupture did not
occur in any of our cases, there is always an inherent risk of uterine
rupture inwomenwith prior cesarean delivery undergoing second-
trimester misoprostol abortion [10e15]. Goyal [10] reported that
the risk of uterine rupture in women with prior cesarean delivery
was 0.28% [95% conﬁdence interval (CI) 0.08e1.00%] and the risk of
uterine rupture in women without prior cesarean delivery was
0.04% (95% CI 0.01e0.20%). Berghella et al [11] also reported an
incidence of uterine rupture of 0.4% (95% CI 0.08e1.67%) in womenthin 12 hours (n ¼ 101) in second trimester termination using misoprostol (n ¼ 101).
Multivariate analysisa
p Odds ratio 95% CI p
0.09 d d d
0.28 d d d
0.04 2.12 1.16e3.88 0.01
0.65 d d d
0.01 d d d
NA NA NA NA
0.10 d d d
0.08 d d d
0.04 0.992 0.986e0.998 0.01
0.30 d d d
l induction within 12 hours.
e rupture of membranes,.
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the authors' conclusion that second-trimester misoprostol abortion
for women with a prior cesarean delivery appears safe [10,11], we
should not ignore the probable higher risk of uterine rupture in
women with a scarred uterus. Thus, appropriate counseling about
the risk of uterine rupture should be given prior to second-
trimester misoprostol abortion, especially for women with a scar-
red uterus; and women with a scarred uterus should receive lower
doses of misoprostol and be instructed not to double the dose if
there is no initial response [16].
Many studies have been conducted to investigate the optimal
route and dosage of misoprostol administration. Given the
considerable variation in reported outcomes and the regimen of
misoprostol adopted, no consensus has been reached. Dickinson
and Evans [17] found that the use of 400 mg vaginal misoprostol
every 6 hours was 1.9-fold more likely to result in delivery within
24 hours compared with oral administration (400 mg orally every 3
hours; rate of delivery 86% vs. 45%). Tang et al [18] introduced a
prospective randomized controlled trial comparing two regimens
(400 mg sublingual or vaginal misoprostol every 3 hours for a
maximum of ﬁve doses); vaginal misoprostol was found to result in
a higher success rate than sublingual misoprostol at 24 hours but a
similar abortion rate at 48 hours.Wong et al [19] suggested that a 3-
hour regimen provides a signiﬁcantly shorter AI and a higher per-
centage of successful abortions within 48 hours than the 6-hour
interval group. In balancing the efﬁcacy and side effects for the
termination of second trimester pregnancy, the WHO recom-
mended the use of vaginal or sublingual misoprostol at 3-hour
intervals; however, no speciﬁc dosing recommendations are
endorsed due to a lack of clinical studies [20]. The Society of Family
Planning also reported that the misoprostol doses of 400 mg are
generally superior to 200 mg or less, and dosing every 3 hours is
superior to less frequent dosing [21].
The combination of mifepristone and misoprostol is only
approved for early ﬁrst trimester termination in Taiwan. It is worth
mentioning that recent studies showed that this combined regimen
is the most effective and fastest for second trimester abortion
[21,22]. Nonetheless, where mifepristone is unavailable or afford-
able, misoprostol alone has also been shown to be effective for
second trimester abortion, although the efﬁcacy is lower than the
combined regimen [21,22].
Dickinson and Doherty [4] showed that younger maternal age
and increasing gestational age were associated with a longer AI in a
consecutive case series involving 1066 women. In our study,
advanced maternal age appeared to have a shorter AI in the uni-
variate analysis (HR ¼ 1.03, p ¼ 0.03), but its signiﬁcance dimin-
ished after adjusting for other confounding factors. There was no
association between gestational age and the AI (HR ¼ 1.04,
p ¼ 0.33); nonetheless, we found that increasing body weight at
birth, which is highly correlated to increasing gestational age
(Spearman's rho ¼ 0.81, p < 0.001), was associated with failed de-
livery within 12 hours (Table 3). Additionally, a higher priming
vaginal dose (400 mg) did not appear to signiﬁcantly reduce the AI
(HR ¼ 1.32, p ¼ 0.17). However, the aforementioned differences
between other authors' studies and our own may be due to our
limited sample size.
The limitations of the present study include its limited sample
size and retrospective nature. Nonetheless, given the substantial
variation in the outcomes and regimens used in the existing liter-
ature, our experience suggested that oral misoprostol at 6-hourintervals following a priming vaginal dose is effective and safe for
second trimester pregnancy termination.
In conclusion, higher parity, intrauterine fetal demise and the
preterm premature rupture of membranes were associated with a
shorter abortion interval. The regimen of 200 mg oral misoprostol at
6-hour intervals following a 200 mg or 400 mg priming vaginal dose
is feasible and efﬁcacious for second trimester pregnancy termi-
nation. These results are valuable to physicians when counseling
women who request second trimester pregnancy termination.
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